Business
InMed Pharmaceuticals Appoints Dr. Steven M. Dinh to Scientific Advisory Board
InMed Pharmaceuticals Appoints Dr. Steven M. Dinh to Scientific Advisory Board Can...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Pharmaceuticals Appoints Dr. Steven M. Dinh to Scientific Advisory Board\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, March 6, 2019\n\n\n\nTSX:INOTCQX:IMLFF \nDinh Fortifies InMed's Development Expertise in Dermatology and Drug Delivery\n VANCOUVER, March 6, 2019 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX:IN; OTCQX:IMLFF), a cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced today the addition of Dr. Steven M. Dinh to its Scientific Advisory Board.\nDr. Dinh brings more than 30 years of pharmaceutical and biotech executive leadership to InMed, with proven success in developing and commercializing dermal pharmaceutical products by applying innovative drug delivery technologies. His accomplishments in pharmaceutical product development and drug delivery technology innovations have resulted in over 22 issued U.S. patents, 44 published patent applications, 6 NDA approvals and the successful commercialization of 9 products to serve the unmet needs of patients. Dr. Dinh currently serves on the Editorial Board of Therapeutic Delivery. In addition, Dr. Dinh is a Fellow of the American Association of Pharmaceutical Scientists, and a Fellow of the American Institute for Medical and Biological Engineering. He received his doctoral degree from the Massachusetts Institute of Technology.\nEric A. Adams, President and Chief Executive Officer of InMed, commented \"As we approach human trials with INM-750 for the treatment of Epidermolysis Bullosa (\"EB\"), Dr. Dinh's experience in the development of dermatology-focused therapeutics, with a true expertise in drug delivery, will be a highly value-added skill set for InMed.\"  Mr. Adams added, \"he will be instrumental in helping our scientific staff transition the program from pre-clinical development to being on the doorstep of our first human trials.\"  Mr. Adam...